FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER (FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER).
Of course, I can help you with that. However, I must clarify that there is no drug called "FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER". "Floxin" is a brand name for ofloxacin, an antibiotic. Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
| Metabolism | Ofloxacin is metabolized in the liver to a limited extent; approximately 5-10% of the drug is metabolized to desmethyl ofloxacin and ofloxacin N-oxide. The cytochrome P450 system is not significantly involved. The drug is primarily excreted unchanged in the urine by glomerular filtration and tubular secretion. |
| Excretion | Primarily renal (80-90% unchanged); biliary/fecal <4%. |
| Half-life | Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). |
| Protein binding | 20-30% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 1.5-2.5 L/kg; indicates extensive tissue penetration. |
| Bioavailability | Intravenous: 100% (not applicable for oral route; product is IV only). |
| Onset of Action | Intravenous: immediate; peak concentrations achieved by end of infusion. |
| Duration of Action | 12 hours (based on dosing interval of every 12 hours for IV administration). |
400 mg (as ofloxacin) intravenously every 12 hours for 7-14 days.
| Dosage form | INJECTABLE |
| Renal impairment | Creatinine clearance 20-50 mL/min: 400 mg IV every 24 hours. Creatinine clearance <20 mL/min: 200 mg IV every 24 hours. |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). Severe impairment (Child-Pugh C): use with caution; consider extended dosing interval. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). Off-label use for specific infections: 15-20 mg/kg/day IV divided every 12 hours, not to exceed 800 mg/day. |
| Geriatric use | No specific dose adjustment solely based on age. Monitor renal function and adjust dose accordingly for decreased creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER (FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Ofloxacin is excreted into human breast milk. The milk-to-plasma ratio is approximately 1.0. The amount ingested by a nursing infant is low (approximately 2-5% of maternal weight-adjusted dose). However, due to potential for arthropathy and other adverse effects in the infant, consider alternatives; if used, monitor infant for gastrointestinal symptoms, rash, and potential cartilage effects. |
| Teratogenic Risk | Fluoroquinolones, including ofloxacin, are associated with arthropathy in immature animals. Human data are limited; however, available studies do not show an increased risk of major malformations. First trimester: No clear evidence of teratogenicity; use only if benefit outweighs risk. Second and third trimesters: Potential risk of fetal cartilage damage; avoid use. Use during pregnancy only if no safer alternative exists. |
■ FDA Black Box Warning
Fluoroquinolones, including ofloxacin, may increase the risk of tendinitis and tendon rupture, especially in patients over 60 years of age, those taking corticosteroids, and those with kidney, heart, or lung transplants. They may also exacerbate muscle weakness in persons with myasthenia gravis. Additionally, they have been associated with peripheral neuropathy and central nervous system effects including seizures, increased intracranial pressure, and toxic psychosis.
| Serious Effects |
["Hypersensitivity to ofloxacin or any fluoroquinolone component. Also contraindicated in patients with a history of tendinopathy or tendon rupture associated with fluoroquinolone use. Avoid use in children under 18 years of age (except for specific indications like anthrax or plague) and in pregnant or nursing women due to potential harm to developing cartilage and other tissues."]
| Precautions | ["Fluoroquinolones should be used only when no alternative treatment options are available for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections due to the risk of disabling and potentially irreversible serious adverse reactions. Other warnings include: CNS effects (seizures, increased intracranial pressure), peripheral neuropathy, tendon damage, exacerbation of myasthenia gravis, QT prolongation, hypersensitivity reactions, phototoxicity, and Clostridium difficile-associated diarrhea. Monitor renal function, especially in the elderly."] |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor for signs of tendonitis, CNS effects (dizziness, confusion), and gastrointestinal disturbances. Fetal: No specific monitoring required; however, consider fetal ultrasound if prolonged use in pregnancy. Neonatal: Monitor for signs of arthropathy if exposure in third trimester. |
| Fertility Effects | In animal studies, fluoroquinolones have been shown to impair fertility at high doses. In humans, no specific fertility impairment has been documented with ofloxacin. However, limited data exist; consider potential for transient impact on sperm quality in males. |